<DOC>
	<DOCNO>NCT00362661</DOCNO>
	<brief_summary>The aim prospective , double-blind , placebo-controlled , cross-over study determine therapeutic efficacy low-dose cortisol symptom chronic posttraumatic stress disorder .</brief_summary>
	<brief_title>Low-dose Cortisol Chronic Posttraumatic Stress Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Female male patient chronic PTSD due adult trauma ; PTSD diagnose accord DSMIV , measure CAPS Age 18 60 History disease state represent contraindication glucocorticoid therapy ( tuberculosis , gastritis , gastric duodenal ulcer , Cushing 's disease , osteoporosis , hypertension , pregnancy ( exclude pregnancy test ) lactation , glaucoma , diabetes mellitus , thrombophilia , acute chronic infection , hyperthyroidism , cirrhosis ) Severe chronic somatic disease Topic glucocorticoid therapy ( large skin part ) Inhaled glucocorticoid Current psychotic , bipolar , substancerelated , severe personality disorder Current severe depressive disorder Severe cognitive impairment history organic mental disorder Evidence PTSD depression immediately prior index trauma Prominent current suicidal homicidal ideation Asylum seek status Body weight &gt; 20 % normal range Changes psychopharmacologic psychotherapeutic management le 8 week start study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>PTSD</keyword>
	<keyword>cortisol</keyword>
	<keyword>memory</keyword>
	<keyword>treatment</keyword>
</DOC>